HRMY Harmony Biosciences Holdings Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: HRMY

Price (delayed)

$40.48

Market cap

$2.36B

P/E Ratio

12.89

Dividend/share

N/A

EPS

$3.14

Enterprise value

$1.96B

?
Relative Growth: Rel. Growth: 85
Relative Strength: Rel. Strength: 79
Relative Valuation: Rel. Valuation: 73
Relative Profitability: Rel. Profitability: 90
Highlights
Harmony Biosciences Holdings's equity has increased by 29% YoY and by 10% from the previous quarter
Harmony Biosciences Holdings's EPS has increased by 24% QoQ
The stock's price to earnings (P/E) is 36% less than its 5-year quarterly average of 20.6 but 18% more than its last 4 quarters average of 11.2
The quick ratio has contracted by 9% YoY and by 3.5% from the previous quarter
The gross margin has contracted by 3.7% YoY
Sector: Healthcare
Industry: Biotechnology
Website: http://www.harmonybiosciences.com
Peers: OPK ORGO

Key stats

What are the main financial stats of HRMY

HRMY stock price

How has the Harmony Biosciences Holdings stock price performed over time
Intraday
-2.53%
1 week
-4.1%
1 month
6.11%
1 year
26.22%
YTD
8.18%
QTD
11.18%

Financial performance

How have Harmony Biosciences Holdings's revenue and profit performed over time
Revenue
$959.9M
Gross profit
$723.99M
Operating income
$230.65M
Net income
$181.27M
Gross margin
75.4%
Net margin
18.9%
The company's revenue rose by 24% YoY and by 7% QoQ
Harmony Biosciences Holdings's net income has increased by 24% from the previous quarter
The operating income has grown by 22% from the previous quarter and by 4% YoY
The gross profit has grown by 20% YoY and by 5% from the previous quarter

Price vs fundamentals

How does HRMY's price correlate with its fundamentals

Growth

What is Harmony Biosciences Holdings's growth rate over time

Valuation

What is Harmony Biosciences Holdings stock price valuation
HRMY P/E details
P/E
12.89
P/B
2.35
P/S
2.44
EV/EBIT
7.7
EV/EBITDA
7.01
EV/Sales
2.04
The stock's price to earnings (P/E) is 36% less than its 5-year quarterly average of 20.6 but 18% more than its last 4 quarters average of 11.2
Harmony Biosciences Holdings's EPS has increased by 24% QoQ
The stock's price to book (P/B) is 57% less than its 5-year quarterly average of 5.6 but 15% more than its last 4 quarters average of 2.1
Harmony Biosciences Holdings's equity has increased by 29% YoY and by 10% from the previous quarter
HRMY's P/S is 43% below its 5-year quarterly average of 4.4 but 20% above its last 4 quarters average of 2.1
The company's revenue rose by 24% YoY and by 7% QoQ

Efficiency

How efficient is Harmony Biosciences Holdings business performance
The ROE is down by 24% YoY but it is up by 17% from the previous quarter
HRMY's return on assets is down by 20% year-on-year but it is up by 18% since the previous quarter
Harmony Biosciences Holdings's return on sales has decreased by 15% YoY but it has increased by 13% QoQ
HRMY's return on invested capital is up by 7% since the previous quarter but it is down by 3.3% year-on-year

Dividends

What is HRMY's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for HRMY.

Financial health

How did Harmony Biosciences Holdings financials performed over time
HRMY's total assets is up by 24% year-on-year and by 8% since the previous quarter
The total liabilities rose by 12% year-on-year and by 3.4% since the previous quarter
The debt is 85% less than the equity
The debt to equity has declined by 32% year-on-year and by 12% since the previous quarter
Harmony Biosciences Holdings's equity has increased by 29% YoY and by 10% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.